Gerhard C. Hildebrandt, MD

Division Chief, Hematology and Blood & Marrow Transplantation

Clinical interests

  • Blood and Marrow Transplantation
  • Hematology

Gerhard C. Hildebrandt, MD

Division Chief, Hematology and Blood & Marrow Transplantation

Biography

Gerhard Carl Hildebrandt, MD, FACP, is a Professor of Medicine at the University of Kentucky and Division Chief of the Division of Hematology and Blood & Marrow Transplantation. He received his medical degree from the Johannes Gutenberg University of Mainz Medical School, Germany, in 1997. Upon completing his doctoral research thesis, he was awarded the "doctor medicinae" with magna cum laude. He then completed a residency in Internal Medicine and a Hematology and Oncology fellowship at the University of Regensburg, Germany and became Bone Marrow Transplant and Hematologic Malignancies Attending at the University of Regensburg. In 2009 he was awarded the "Habilitation", the highest academic qualification a scholar can achieve by own pursuit in Germany.

After moving to the United States in 2009, Hildebrandt was faculty member at the Louisiana State University in Shreveport, and at the University of Utah. He was the director of the bone marrow transplant program at LSUHSC Shreveport and director of the Utah Blood and Marrow Transplant program at the Huntsman Cancer Institute/University of Utah, before moving to Kentucky.

Hildebrandt is member of ASH, ASCO, ASBMT, AACR, the author of more than 40 articles, books and book chapters, and strongly involved in clinical trials.

Hildebrandt focusses on patients with cancers of the blood and lymph system, patients before and after blood or marrow stem cell transplantation and on patients suffering from acute and chronic graft versus host disease.

Personal statement

I want my patients to know that the entire team at Markey Cancer Center really cares for them. The opportunity to bring light into a patient’s life at a time when they’re uncertain is very rewarding. We are here to give them the time they need, there's no rush. My favorite slogan is always, "There's no rushing medicine.” We do not rush patients in and out. That's not what we're here for, we're here to help. We form long-lasting relationships with our patients at Markey Cancer Center, and this is unique and very satisfying for me.

Faculty rank

Professor of Medicine

Education

Degree
Johannes-Gutenberg Universitaet, Mainz, Germany

Residency
Internal Medicine, Universitatsklinikum Regensburg, Germany

Fellowship
Hematology/Oncology, Universitatsklinikum Regensburg, Germany
Postdoctoral Research Training: Blood and Marrow Transplantation, University of Michigan, Ann Arbor

Hematology and Blood & Marrow Transplantation

Markey Cancer Center
Ben F. Roach Cancer Care Facility
First Floor, Room CC140
800 Rose St.
Lexington KY 40536-0093

HBCicon120x123
This is a clinic of the University of Kentucky Hospital, also known as UK Albert B. Chandler Hospital. Read more »

Call 800-333-8874
Call 859-257-6006
Fax 859-323-4607

After hours, call 859-323-5321.

The Ben F. Roach Cancer Center is located adjacent to UK Chandler Hospital on Rose Street, and a small parking lot and drop-off circle are accessible next to the building.

Directions to Markey Cancer Center - Ben F. Roach Cancer Care Facility »


Insurance information

Insurance policies can vary widely. Please check with your doctor/clinic for specific insurance information before your visit or procedure to avoid unexpected out-of-pocket costs. See list of insurers »

 
  1. Reddy P, Teshima T, Hildebrandt G, Duffner U, Maeda Y, Cooke KR, Ferrara JL (2002). Interleukin 18 preserves a perforin-dependent graft-versus-leukemia effect after allogeneic bone marrow transplantation. Blood, 100(9), 3429-31.
  2. Reddy, P, Teshima, T, Hildebrandt, G, Williams, DL, Liu, C, Cooke, K, Ferrara, JLM (2003). Pretreatment of donors with Interleukin-18 attenuates acute graft-versus-host diserase via STAT6 and preserves graft-versus-leukemia effects. Blood, 101(7), 2877-85.
  3. Duffner U, Lu B, Hildebrandt GC, Teshima T, Williams DL, Reddy P, Ordemann R, Clouthier SG, Lowler K, Liu C, Gerard C, Cooke KR, Ferrara JL (2003). Role of CXCR3-induced donor T-cell migration in acute GVHD. Exp Hematol, 31(10), 897-902.
  4. Hildebrandt GC, Duffner UA, Olkiewicz KM, Corrion LA, Willmarth NE, Williams DL, Clouthier SG, Hogaboam CM, Reddy PR, Moore BB, Kuziel WA, Liu C, Yanik G, Cooke KR (2004). A critical role for CCR2/MCP-1 interactions in the development of idiopathic pneumonia syndrome after allogeneic bone marrow transplantation. Blood, 103(6), 2417-26.
  5. Hildebrandt GC, Olkiewicz KM, Corrion LA, Chang Y, Clouthier SG, Liu C, Cooke KR (2004). Donor-derived TNF-alpha regulates pulmonary chemokine expression and the development of idiopathic pneumonia syndrome after allogeneic bone marrow transplantation. Blood, 104(2), 586-93.
  6. Hildebrandt GC, Corrion LA, Olkiewicz KM, Lu B, Lowler K, Duffner UA, Moore BB, Kuziel WA, Liu C, Cooke KR (2004). Blockade of CXCR3 receptor:ligand interactions reduces leukocyte recruitment to the lung and the severity of experimental idiopathic pneumonia syndrome. J Immunol, 173(3), 2050-9.
  7. Gerbitz, A, Nickoloff, BJ, Olkiewicz, K, Willmarth, NE, Hildebrandt, GC, Liu, C, Kobzik, L, Eissner, G, Holler, E, Ferrara, JL, Cooke, KR (2004 Aug 27). A role for tumor necrosis factor-alpha mediated endothelial apoptosis in the development of experimental idiopathic pneumonia syndrome. Transplantation, 78(4), 494-502.
  8. Hildebrandt GC, Olkiewicz KM, Choi S, Corrion LA, Clouthier SG, Liu C, Serody JS, Cooke KR (2005). Donor T-cell production of RANTES significantly contributes to the development of idiopathic pneumonia syndrome after allogeneic stem cell transplantation. Blood, 105(6), 2249-57.
  9. Gerbitz A, Ewing P, Olkiewicz K, Willmarth NE, Williams D, Hildebrandt G, Wilke A, Liu C, Eissner G, Andreesen R, Holler E, Guo R, Ward PA, Cooke KR (2005). A role for CD54 (intercellular adhesion molecule-1) in leukocyte recruitment to the lung during the development of experimental idiopathic pneumonia syndrome. Transplantation, 79(5), 536-42.
  10. Ewing P, Miklos S, Olkiewicz KM, Muller G, Andreesen R, Holler E, Cooke KR, Hildebrandt GC (2007). Donor CD4+ T-cell production of tumor necrosis factor alpha significantly contributes to the early proinflammatory events of graft-versus-host disease. Exp Hematol, 35(1), 155-63.
  11. Ewing P, Hildebrandt GC, Planke S, Andreesen R, Holler E, Gerbitz A (2007). Cobalt protoporphyrine IX-mediated heme oxygenase-I induction alters the inflammatory cytokine response, but not antigen presentation after experimental allogeneic bone marrow transplantation. Int J Mol Med, 20(3), 301-8.
  12. Choi SW, Hildebrandt GC, Olkiewicz KM, Hanauer DA, Chaudhary MN, Silva IA, Rogers CE, Deurloo DT, Fisher JM, Liu C, Adams D, Chensue SW, Cooke KR (2007). CCR1/CCL5 (RANTES) receptor-ligand interactions modulate allogeneic T-cell responses and graft-versus-host disease following stem-cell transplantation. Blood, 110(9), 3447-55.
  13. Hildebrandt GC, Granell M, Urbano-Ispizua A, Wolff D, Hertenstein B, Greinix HT, Brenmoehl J, Schulz C, Dickinson AM, Hahn J, Rogler G, Andreesen R, Holler E (2008). Recipient NOD2/CARD15 variants: a novel independent risk factor for the development of bronchiolitis obliterans after allogeneic stem cell transplantation. Biol Blood Marrow Transplant, 14(1), 67-74.
  14. Hildebrandt GC, Choi SW, Mueller G, Olkiewicz KM, Moore BB, Cooke KR (2008). The absence of donor-derived IL-13 exacerbates the severity of acute graft-versus-host disease following allogeneic bone marrow transplantation. Pediatr Blood Cancer, 50(4), 911-4.
  15. Hildebrandt GC, Olkiewicz KM, Corrion L, Clouthier SG, Pierce EM, Liu C, Cooke KR (2008). A role for TNF receptor type II in leukocyte infiltration into the lung during experimental idiopathic pneumonia syndrome. Biol Blood Marrow Transplant, 14(4), 385-96.
  16. Miklos S, Mueller G, Chang Y, Schubert TE, Holler E, Hildebrandt GC (2008). Pulmonary function changes in experimental graft-versus-host disease of the lung. Biol Blood Marrow Transplant, 14(9), 1004-16.
  17. Miklos S, Mueller, G, Chang, Y, Bouazzaoui A, Spacenko, E, Schubert, TE, Grainger, DJ, Holler, E, Andreesen, R, Hildebrandt, GC (2009 Apr). The usage of broad spectrum chemokine inhibitor NR58-3.14.3 reduces the severity of pulmonary and hepatic graft-versus-host- disease. Int J Hematol.
  18. Chang YY, Greinix HT, Dickinson AM, Wolff D, Jackson GH, Andreesen R, Holler E, Hildebrandt GC (2009). G to C transition at position -173 of MIF gene of the recipient is associated with reduced relapse rates after allogeneic stem cell transplantation. Cytokine, 48(3), 218-25.
  19. Wolff D, Steiner B, Hildebrandt G, Edinger M, Holler E (2009). Pharmaceutical and cellular strategies in prophylaxis and treatment of graft-versus-host disease. [Review]. Curr Pharm Des, 15(17), 1974-97.
  20. Bouazzaoui A, Spacenko E, Mueller G, Miklos S, Huber E, Holler E, Andreesen R, Hildebrandt GC (2009). Chemokine and chemokine receptor expression analysis in target organs of acute graft-versus-host disease. Genes Immun, 10(8), 687-701.
  21. Wolff, D, Gerbitz, A, Ayuk, F, Kiani, A, Hildebrandt, GC, Vogelsang, GB, Elad, S, Lawitschka, A, Socie, G, Pavletic, SZ, Holler, E, Greinix H (2010 Dec). Consensus conference on clinical practice in chronic graft-versus-host disease (GVHD): First-line and topical treatment of chronic GVHD. [Review]. Biol Blood Marrow Transplant, 16(12), 1611-28.
  22. Bouazzaoui A, Spacenko E, Mueller G, Huber E, Schubert T, Holler E, Andreesen R, Hildebrandt GC (2011). Steroid treatment alters adhesion molecule and chemokine expression in experimental acute graft-vs.-host disease of the intestinal tract. Exp Hematol, 39(2), 238-249.e1.
  23. Hildebrandt GC, Fazekas T, Lawitschka A, Bertz H, Greinix H, Halter J, Pavletic SZ, Holler E, Wolff D (2011). Diagnosis and treatment of pulmonary chronic GVHD: report from the consensus conference on clinical practice in chronic GVHD. [Review]. Bone Marrow Transplant, 46(10), 1283-95.
  24. Palaniyandi, S, Radhakrishnan, SV, Karsson FJ, Stokes, KY, Kittan, N, Huber, E, Hildebrandt, GC (2013 Apr 15). Murine cytomegalovirus immediate - early 1gene expression correlates with increased GVHD after allogeneic hematopoietic cell transplantation in recipients reactivating from latend infection. PLoS ONE, 8(4), e61841.
  25. Wolff, D, Ayuk, F, Elmaagacli, A, Bertz H, Lawitschka, A, Schleuning, M, Meyer, RG, Gerbitz, A, Hilgendorf, I, Hildebrandt, GC, Edinger, M, Klein, S, Halter, J, Mousset, S, Holler, E, Greinix, H (2013 May). Current practice in diagnosis and treatment of acute graft-versus host-disease - results from a survey among German-Austrian-Swiss HSCT centers. Biol Blood Marrow Transplant, 19(5), 767-76.
  26. Beier F, Arbter K, Kittan NA, Andreesen R, Krause SW, Holler E, Hildebrandt GC (2014). Regression of eosinophil counts after diagnosis of chronic graft-versus-host disease as a potential marker for improved clinical outcome. Mol Clin Oncol, 2(1), 81-86.
  27. Schwab L, Goroncy L, Palaniyandi S, Gautam S, Triantafyllopoulou A, Mocsai A, Reichardt W, Karlsson FJ, Radhakrishnan SV, Hanke K, Schmitt-Graeff A, Freudenberg M, von Loewenich FD, Wolf P, Leonhardt F, Baxan N, Pfeifer D, Schmah O, Schonle A, Martin SF, Mertelsmann R, Duyster J, Finke J, Prinz M, Henneke P, Hacker H, Hildebrandt GC, Hacker G, Zeiser R (2014). Neutrophil granulocytes recruited upon translocation of intestinal bacteria enhance graft-versus-host disease via tissue damage. Nat Med, 20(6), 648-54.
  28. Venniyil Radhakrishnan, S, Palaniyandi, S, Gunnar, M, Miklos, S, Hager, M, Spacenko, E, Karlsson, F, Huber, E, Kittan, N, Hildebrandt, GC (In Press). Preventive azithromycin treatment reduces noninfectious lung injury and acute graft versus host disease in a murine model of allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant, in press.
  29. Radhakrishan, SV; Hildebrandt, GC: A call to arms: a critical need for interventions to limit pulmonary toxicity in the stem cell transplantation population. Current Hematologic Malignancy Reports (in press)